Science
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo – Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies w
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in Nature Communications that reportspreclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo.
The study, Mitochondrial targeted meganuclease as a platform to eliminate…
-
General24 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
General22 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell
-
Noosa News22 hours agoAlleged Gold Coast conman exposed: elderly woman’s life savings vanish in shocking scam
-
Noosa News22 hours agoHow Roosters star Eliza Lopamaua found her way to NRLW